Evidence map›Paper›PMID 28419653›Full record

ArticleJournal of viral hepatitis2017

HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.

E Papasavvas, L Azzoni, X Yin, Q Liu, J Joseph, A Mackiewicz, B Ross, K M Lynn, J M Jacobson, K Mounzer and 2 more

Abstract read
In one paragraph

Article in Journal of viral hepatitis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

E PapasavvasThe Wistar Institute, Philadelphia, PA, USA.
L AzzoniThe Wistar Institute, Philadelphia, PA, USA.
X YinThe Wistar Institute, Philadelphia, PA, USA.
Q LiuThe Wistar Institute, Philadelphia, PA, USA.
J JosephThe Wistar Institute, Philadelphia, PA, USA.
A MackiewiczThe Wistar Institute, Philadelphia, PA, USA.
B RossThe Wistar Institute, Philadelphia, PA, USA.
K M LynnPresbyterian Hospital-University of Pennsylvania hospital, Philadelphia, PA, USA.
J M JacobsonTemple University, Lewis Katz School of Medicine, Philadelphia, PA, USA.
K MounzerJonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, PA, USA.
J R KostmanJohn Bell Health Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, PA, USA.
L J MontanerThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-5799-6759
The Wistar Institute · USPhiladelphia Fight · USHospital of the University of Pennsylvania · USTemple University · US

Funding

NK/DC Cross-Talk and Antiviral ResponseR01AI073219 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J · 2008 to 2011
$3.0M
NIAID NIH HHS R01 AI073219
6 · The paper itself

Abstract

The impact of hepatitis C virus (HCV) RNA levels on immune status in chronically HCV mono-infected when compared to HIV/HCV co-infected on antiretroviral therapy (ART) remains poorly understood. A total of 78 African American subjects HCV viraemic/naïve to HCV treatment (33 HCV genotype 1 mono-infected, 45 ART-treated HIV/HCV genotype 1 co-infected) were studied. Clinical and liver enzyme measurements were performed. Whole blood was analysed for immune subset changes by flow cytometry. Peripheral blood mononuclear cells (PBMC) were used for same-day constitutive and in vitro Interferon (IFN)-α-induced signal transducer and activator of transcription (STAT) phosphorylation, K562 target cell lysis and K562 target cell recognition-mediated IFN-γ production. Statistical analysis was performed using R (2.5.1) or JMP Pro 11. While both groups did not differ in the level of liver enzymes, HIV/HCV had higher T-cell activation/exhaustion, and constitutive STAT-1 phosphorylation compared to HCV. In contrast, CD4

Indexed as

CoinfectionHIV InfectionsViremiaAntiretroviral Therapy, Highly ActiveAntiviral AgentsBiomarkersCD4 Lymphocyte CountCytokinesCytotoxicity, ImmunologicDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunophenotypingKiller Cells, NaturalAntiviral AgentsBiomarkersCytokinesSTAT1 protein, humanSTAT1 Transcription FactorHCV viral loadhepatitis C virusHIV/HCVnatural killerT cells

Identifiers

PMID28419653
PMCPMC5589504
OpenAlexW2607316912

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.